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Abstract
Objective
To assess the ability of the urinary biomarkers IGFBP7 (insulin-like growth factor-binding
protein 7) and TIMP-2 (tissue inhibitor of metalloproteinase 2) to early predict acute kidney
injury (AKI) in high-risk surgical patients.
Introduction
Postoperative AKI is associated with an increase in short and long-term mortality. Using
IGFBP7 and TIMP-2 for early detection of cellular kidney injury, thus allowing the early initia-
tion of renal protection measures, may represent a new concept of evaluating renal
function.
Methods
In this prospective study, urinary [TIMP-2]×[IGFBP7] was measured in surgical patients at
high risk for AKI. A predefined cut-off value of [TIMP-2]×[IGFBP7]>0.3 was used for as-
sessing diagnostic accuracy. Perioperative characteristics were evaluated, and ROC analy-
ses as well as logistic regression models of risk assessment were calculated with and
without a [TIMP-2]×[IGFBP7] test.
Results
107 patients were included in the study, of whom 45 (42%) developed AKI. The highest me-
dian values of biomarker were detected in septic, transplant and patients after hepatic sur-
gery (1.24 vs 0.45 vs 0.47 ng/l2/1000). The area under receiving operating characteristic
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curve (AUC) for the risk of any AKI was 0.85, for early use of RRT 0.83 and for 28-day mor-
tality 0.77. In a multivariable model with established perioperative risk factors, the [TIMP-
2]×[IGFBP7] test was the strongest predictor of AKI and significantly improved the risk as-
sessment (p<0.001).
Conclusions
Urinary [TIMP-2]×[IGFBP7] test sufficiently detect patients with risk of AKI after major non-
cardiac surgery. Due to its rapid responsiveness it extends the time frame for intervention to
prevent development of AKI.
Introduction
Postoperative acute kidney injury (AKI) is one of the most common postoperative complica-
tions and is associated with an increase in hospital mortality and decreased survival for up to
15 years after surgery [1–5]. The prognosis of patients with AKI is still poor, intervention for
prevention and therapy of AKI are currently only initiated in the late phase of already estab-
lished injury; therefore, benefits remain limited [6].
Using biomarkers for the early detection of cellular injury, thus allowing the early initiation
of renal protection measures, may represent a new concept of evaluating renal function in criti-
cally ill patients [7,8]. Combination of two novel urinary cell-cycle arrest biomarkers, i.e. the
insulin-like growth factor-binding protein 7 and the tissue inhibitor of metalloproteinase-2
([TIMP-2]×[IGFBP7] panel) was described and validated in two multicenter studies for predic-
tion of risk of moderate and severe AKI (AKI stage 2 and 3 according to KDIGO 2012 classifi-
cation) in critically ill patients. Both TIMP2 and IGFBP7 are markers of cellular stress in the
early phase of tubular cell injury caused by a wide variety of insults (inflammation, ischemia,
oxidative stress, drugs, and toxins) [9–12]. Therefore, both markers are involved in the process
of G1 cell-cycle arrest that prevents cells from dividing in the case of damage to the DNA until
such damage can be repaired [13]. Importantly, both biomarkers appear as “alarm” proteins
for other nearby cells in a paracrine fashion [14,15]. These two biomarkers performed better in
prediction of AKI than NGAL (AUC 0.64), KIM-1 (AUC 0.69), IL-18 (AUC 0.76), L-FABP
(AUC 0.66), or Cystatin C (AUC 0.63) [16,17]. In cardiac surgery patients act [TIMP-
2]×[IGFBP7] as a sensitive predictor of AKI and may help to predict renal recovery after AKI
using cutoff of 0.5 [18].
The aim of the current study was to evaluate, how the biomarker would perform in non-car-
diac surgical patients, if assessed in very early phase after surgery by using a validated cutoff
of> 0.3. Moreover, we investigated the performance of the [TIMP-2]×[IGFBP7] test across
different severities of AKI (including or excluding stage 1). In addition to perioperative risk fac-
tors, we assessed the risk stratification in conjunction with bedside clinical parameters at the
time of biomarker assessment. Finally we tested the relation between early cell cycle arrest in
the kidney and outcome in surgical patients.
Methods
Patients
120 patients were evaluated between May 2013 and November 2013 in the multidisciplinary
surgical ICU of a tertiary care university hospital; 13 patients were excluded because they had
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already developed AKI before biomarker assessment (based on an increase in SCr>0.3 after
surgery) (Fig. 1). The study was approved by the local Institutional Review Board (Ethics Com-
mittee, University of Regensburg, no. 13-101-0191). Written consent was obtained from all pa-
tients or from their next of kin. All patients over the age of 18 years, who had received major
non-cardiac surgery, were transported to the ICU immediately after the completion of surgery.
Additionally, the patients had at least one risk factor for AKI, such as trauma, sepsis, critical
Fig 1. Study design and flow diagram. 1 High Risk for AKI—major surgery and one additional risk factor—critical illness, sepsis, major trauma, chronic
renal disease or use of radiocontrast agent.2 AKI was defined according to KDIGO 2012 criteria by creatinine increase of> 0.3 after surgery.
doi:10.1371/journal.pone.0120863.g001
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illness, chronic renal disease, and use of an intravenous radiocontrast agent and were thus eligi-
ble for inclusion into the study. Critical illness was defined as requirement of inotropic support
or mechanical ventilation at the time of admission to the ICU. Patients were excluded if they
had end-stage renal disease or developed AKI during the period of time until biomarker
assessment.
Measurements
Urine samples for biomarker assessment were taken from the urinary catheter of eligible patients
soon after the transfer from the operating theatre to the ICU. The level of [TIMP-2]×[IGFBP7]
was measured by means of the immunoassay method integrated in the Astute 140 Meter Kit (As-
tute Medical Inc., San Diego, CA, USA). All values for [TIMP-2]×[IGFBP7] are reported in units
of (ng/mL)2 /1000. In accordance with the validation study, the cut-off of [TIMP-2]×[IGFBP7]
>0.3 was used for predicting AKI [16]. The incidence and severity of AKI based on SCr, UO, and
provision of RRT were assessed over the first 48 h after admission. SCr was measured before sur-
gery, at admission to the ICU, and then daily during the ICU stay. UO was assessed hourly dur-
ing the first 48 h. In addition, we recorded different variables, such as type of surgery or diagnosis
at admission, the Simplified Acute Physiology Score II (SAPS-II) at admission, age, sex, weight
(kg), height (m), creatinine level and norepinephrine dosage (μg/ kg/min) at ICU admission,
mean arterial pressure (MAP), hemoglobin level (g/dL), cumulative fluid balance (mL/24 h), and
urine production (mL/kg/h) at the time of biomarker assessment.
Statistical methods
Continuous variables are presented as a mean (standard deviation [SD]), and categorical data
as frequency counts (percentages). [TIMP-2]×[IGFBP7] values are presented as median values
(interquartile ranges [IQR]) and as range because of the skewed distribution of the data. Con-
tinuous variables were compared by the Student's t test or the Mann-Whitney U test, depend-
ing on the distribution of the observed data. Receiver-operating characteristic (ROC) analyses
were conducted to differentiate between patient groups ((all stages of AKI [yes/no], moderate
or severe AKI [yes/no], RRT [yes/no], and ICU mortality [yes/no]), and the optimal cutoff was
estimated according to the Youden Index. Estimates for the area under the curve (AUC) with
the corresponding 95% confidence interval (CI) were reported as well as sensitivity and speci-
ficity. Multivariable logistic regression models were calculated by means of odds ratios (OR’s)
and corresponding 95% CI’s to assess the predictive ability of [TIMP-2]×[IGFBP7] for AKI de-
velopment, for use of RRT and for 28-day mortality. To compare the fit of two nested models,
we calculated AUCs of the predicted probabilities and conducted a likelihood-ratio test. A
value of P0.05 was considered to indicate statistical significance. All analyses were done with
IBM SPSS Statistics 21.0.0.1 and R (version 3.0.2).
Results
Baseline and clinical characteristics; ROC analysis
The baseline characteristics of the patients are shown in Table 1. The mean time between ad-
mission to the ICU and biomarker assessment was 245 minutes (SD 152). 45 (42%) patients de-
veloped AKI in the first 48 h of their ICU stay, 24 (22%) patients had moderate and severe AKI
(stage 2 and 3), and 10 (9%) patients required RRT within the first 48 h after admission. 8 (8%)
patients died in the ICU and 10 (9.3%) patients within the first 28 days after surgery. In the
hepatobiliary subgroups of patients 1 of 12 developed AKI, 6 of 14 transplant patients, 4 of 13
cancer patients, 16 of 33 after vascular surgery, 9 of 21 major trauma patients and 8 of 10 septic
TIMP-2 and IGFBP7 after Major Surgery
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patients (Table 2). The median value of [TIMP-2]×[IGFBP7] in patients without AKI was 0.19
(IQR 0.1, 0.34); in patients with AKI stage 1: 0.51 (IQR 0.38, 2.66); 1.24 (IQR 0.56, 3.00) in pa-
tients with stage 2 and 3; and 1.35 (IQR 0.76, 3.39) in patients who subsequently received RRT.
The RRT was started in the meantime of 22.06 hours (SD 14.8) after biomarker assessment
and< 48 hours after ICU admission (in 5 patients due to refractory hyperkalemia, in 1 patient
due to severe acidosis and in 4 patients due to oliguria< 0.3 ml/kg/h for> 24hours). The AUC
for predicting AKI (all stages) was 0.85 (95% CI 0.78, 0.93) and 0.85 (95% CI 0.78, 0.92) for
predicting AKI stage 2 and 3, 0.83 for the early use of RRT and 0.77 for 28-day mortality (95%
CI 0.67, 0.80) (Fig. 2).
Bedside perioperative characteristics and postoperative clinical
variables with and without the [TIMP-2]×[IGFBP7] test
Table 3 shows the performance of the [TIMP-2]×[IGFBP7] test in combination with estab-
lished perioperative risk factors for AKI, such as age, severity of illness score SAPS II, and
Table 1. Patient characteristics (n = 107).
Baseline characteristics Mean (SD)
Age (years) 60.03 (14.78)
BMI (kg/m2) 27.45 (5.64)
Weight (kg) 81.49 (18.26)
SAPS II 22.13 (9.63)
ICU (days) 9.50 (14.05)
Chronic kidney disease 18 (15%)
Creatinine at admission ICU 1.13 (0.60)
AKI 45 (42%)
AKI stage 2 and 3 24 (22%)
RRT <48 hours after
admission
10 (9%)
28-day mortality 10 (9%)
Diagnosis/Surgery at
admission
Frequency
(percentage)
(IGFBP-7)*(TIMP-2) values (Median (IQR),
min-max)
Hepatobiliary 12 (11%) 0.46 (0.30, 0.78), 0.22–1.78
Transplant 14 (13%) 0.45 (0.15, 1.50), 0.04–4.18
Cancer 13 (12%) 0.22 (0.11, 1.99), 0.02–9.50
Vascular 33 (31%) 0.27 (0.13, 0.36), 0.02–0.87
Severe Trauma 21 (20%) 0.38 (0.11, 1.27), 0.04–9.59
Sepsis 10 (9%) 1.24 (0.29, 2.83), 0.08–5.91
Other 4 (4%)
(IGFBP-7)*(TIMP-2) values Median (IQR), min-max
Ø AKI 0.19 (0.10, 0.34), 0.02–1.79
AKI Stage 1 0.51 (0.29,2.29), 0.04–9.50
AKI Stage 2 and 3 1.24 (0.56, 3.00), 0.32–9.59
RRT <48 hours after
admission
1.35 (0.76, 3.39), 0.44–4.18
BMI, body mass index; SAPS II, Simpliﬁed Acute Physiology Score II; ICU, intensive care unit; AKI, acute
kidney injury; RRT, renal replacement therapy; SD, standard deviation; IGFBP7, insulin-like growth factor-
binding protein 7; TIMP-2, tissue inhibitor of metalloproteinase.
doi:10.1371/journal.pone.0120863.t001
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creatinine level at ICU admission. Addition of biomarkers significantly improved the risk as-
sessment of AKI; AUC increased from 0.72 (95% CI 0.62, 0.81) to 0.88 (0.82, 0.94), p<0.001,
and AKI Stage 2 and 3 AUC 0.81 (0.70, 0.90) improved to 0.87 (0.79, 0.95), p<0.001.
Table 4 shows a multivariable logistic regression model with bedside postoperative parame-
ters at the time of biomarker assessment alone and by adding the [TIMP-2]×[IGFBP7] test for
predicting any AKI, AKI Stage 2 and 3, and the early use of RRT. By adding the [TIMP-
2]×[IGFBP7] test to the postoperative clinical factors, the predictive power for AKI significant-
ly improved (P<0.001); AUC 0.81 (95% CI 0.73, 0.90) increased to 0.89 (95% CI 0.83, 0.96).
Values for AKI Stage 2 and 3 were AUC 0.87 (95% CI 0.78. 0.96) increasing to 0.89 (95% CI
0.81, 0.97), p = 0.002. The same effect was observed for the use of RRT, for which AUC 0.85
(0.69, 1.00) increased to AUC 0.86 (0.73, 0.99) (P = 0.035).
Discussion
Our study evaluated the use of the novel urinary cell-cycle arrest biomarkers [TIMP-
2]×[IGFBP7] in patients with a high risk of AKI (at least one additional risk factor according to
the KDIGO recommendation [19]) after major non-cardiac surgery.
The mean findings of our study were: 1) In addition to good prediction for moderate and se-
vere AKI, as showed in the validation study, we found that any AKI (including and excluding
stage 1) can be predicted in non-cardiac surgery patients with a predefined cutoff of 0.3. 2)
Compared to the Sapphire study16, in which biomarkers were tested up to 12 hours after ad-
mission, risk stratification in our study occurred very early after surgery within the mean time
of 245 minutes. These results illustrate the rapid responsiveness of the test. 3) In the multivari-
able model with perioperative risk factors and bedside clinical parameters, [TIMP-
2]×[IGFBP7] test was the strongest predictor and significantly improved the detection of surgi-
cal patients with an increased risk of AKI. 4) Early cell cycle arrest after surgery may be associ-
ated with adverse outcome. 5) Patients after hepatic surgery showed increased median values
of biomarkers, and only one patient developed AKI within 48 hours after surgery. These find-
ings suggest that the early correction of hypovolemia, which is routinely performed postopera-
tively in this group of patients, may reverse cell cycle arrest and prevent the development of
AKI.
In the present study, higher median values of [TIMP-2]×[IGFBP7] after admission were as-
sociated with an increased degree of renal injury within 48 hours after surgery. Patients with
AKI stage 1 had the lowest median values, and patients requiring RRT had the highest median
[TIMP-2]×[IGFBP7] test results. This association was crucial and showed that the degree of
Table 2. Baseline characteristics of the study subgroups.
Hepatic (n = 12) Transplant (n = 14) Cancer (n = 13) Vascular (n = 33) Trauma (n = 21) Sepsis (n = 10)
Age 61.75 (SD 15.33) 54.50 (SD 11.31) 59.23 (SD 12.58) 64.55 (SD 9.42) 54.71 (SD 23.13) 64.30 (SD 9.66)
AKI yes 1 (8%) 6 (43%) 4 (31%) 16 (49%) 9 (43%) 8 (80%)
[TIMP2xIGFBP7]>0.3 9 (75%) 8 (57%) 5 (39%) 14 (42%) 13 (62%) 8 (80%)
SAPS II 15.58 (SD 8.68) 20.14 (SD 9.17) 18.90 (SD 4.83) 23.94 (SD 9.52) 23.71 (SD 8.14) 31.80 (SD 9.67)
Fluid balance (ml) 1419 (SD 1170) 1121 (SD 902) 939 (SD 1122) 1845 (SD 1265) 1518 (SD 1572) 2942 (SD 2698)
MAP (mmHg) 77.61 (SD 12.36) 81.32 (SD 11.82) 77.61 (SD 10.74) 78.61 (SD 8.09) 77.11 (SD 11.71) 76.99 (SD 5.09)
Hemoglobin (g/dl) 10.97 (SD 1.82) 9.57 (SD 1.52) 10.01 (SD 2.17) 9.80 (SD 1.60) 9.01 (SD 1.17) 9.14 (SD 1.38)
Urine Output (ml/kg/h) 1.28 (SD 0.64) 1.29 (SD 0.89) 1.47 (SD 0.72) 1.31 (SD 0.62) 1.68 (SD 0.84) 1.05 (SD 0.73)
Data are mean (SD) or n (%). Fluid 24 = Fluid balance in the ﬁrst 24 hours after ICU admission; MAP = mean "mean arterial pressure" over the ﬁrst 24
hours; Hemoglobin = mean hemoglobin level in the ﬁrst 24 hours; Urine output = mean urine output ml/kg/h in ﬁrst 24 hours.
doi:10.1371/journal.pone.0120863.t002
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early cellular damage was associated with the severity of the functional defect occurring at a
later stage.
Our results provide a new perspective on the performance of biomarkers in combination
with perioperative parameters. Established risk factors for AKI are severity of the illness score,
creatinine at admission, and age. In addition, we tested for the first time clinical parameters
that help clinicians identify high-risk patients in the daily routine and that are associated with
increased incidence or severity of AKI (urine output, hemoglobin level, mean arterial pressure,
fluid balance, and use of vasopressors) [20–24]. In both models, use of the [TIMP-
2]×[IGFBP7] test significantly improved AKI prediction. Moreover, the AUC for predicting
AKI with urinary biomarker alone was higher than the prediction with perioperative risk fac-
tors in both clinical models (0.85 for biomarker alone vs. 0.72 for perioperative and 0.81 for
Fig 2. Area under the curve (AUC) and the best cut-offs for predicting AKI, AKI Stage 2 and 3, early use of RRT and 28-daysmortality.
doi:10.1371/journal.pone.0120863.g002
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Table 3. Multivariable logistic regression model of perioperative parameters at the time of biomarker assessment with and without the (TIMP-2)*
(IGFBP7) for risk assessment of AKI, AKI Stage 2 and 3, RRT and 28-daymortality.
AKI RRT 28 days mortality AKI 2, 3
Variable OR (95%-CI) p-
value
OR (95%-CI) p-
value
OR (95%-CI) p-
value
OR (95%-CI) p-
value
Age (per year) 1.02 (0.98,
1.05)
.400 1.03 (0.97,
1.11)
0.332 1.01 (0.96,
1.06)
0.757 1.00 (0.96,
1.05)
0.865
SAPS II 1.08 (1.02,
1.14)
.013 1.14 (1.03,
1.25)
0.010 1.12 (1.02,
1.22)
0.014 1.13 (1.05,
1.21)
0.001
Creatinine (per 0.1 unit log) 1.09 (0.85,
1.36)
.528 0.78 (0.50,
1.23)
0.286 0.72 (0.45,
1.15)
0.165 0.84 (0.60,
1.17)
0.303
(IGFBP7) * (TIMP-2) level (per 0.1 unit
log)
1.36 (1.19,
1.54)
<.001 1.13 (0.99,
1.30)
0.077 1.07 (0.94,
1.22)
0.283 1.23 (1.10,
1.38)
<0.001
AUC (95%-CI) 0.881 (0.817, 0.944) 0.893 (0.817, 0.969) 0.825 (0.710, 0.940) 0.868 (0.793, 0.944)
AUC (95%-CI) without (IGFBP7) * (TIMP-
2) level
0.715 (0.617, 0.813) 0.843 (0.731, 0.956) 0.799 (0.661, 0.937) 0.805 (0.709, 0.902)
p-value* <0.001 0.067 0.279 <0.001
*Likelihood-ratio test (comparing the ﬁt of both models)
AKI, acute kidney injury; RRT, renal replacement therapy; IGFBP7, insulin-like growth factor-binding protein 7; TIMP-2, tissue inhibitor of
metalloproteinase;
MAP, mean arterial pressure; AUC, area under the curve; CI, coincidence interval; OR, odds ratio.
doi:10.1371/journal.pone.0120863.t003
Table 4. Multivariable logistic regression model of bedside postoperative parameters at the time of biomarker assessment with and without the
(TIMP-2)*(IGFBP7) for risk assessment of AKI, use of RRT, 28-daysmortality and AKI 2,3.
AKI RRT 28 days mortality AKI stage 2, 3
Variable OR (95%-CI) p-
value
OR (95%-CI) p-
value
OR (95%-CI) p-
value
OR (95%-CI) p-
value
Urine Output (per 1ml/Kg/h) 0.38 (0.15,
0.96)
.041 0.19 (0.03,
1.17)
.073 0.92 (0.33,
2.56)
0.872 0.12 (0.03,
0.56)
0.007
MAP (per 1mmHg) 1.02 (0.97,
1.06)
.459 1.02 (0.96,
1.09)
.478 1.01 (0.95,
1.07)
0.838 1.02 (0.97,
1.08)
0.407
Hemoglobin (per 1g/dl) 0.94 (0.71,
1.23)
.640 1.02 (0.70,
1.50)
.909 0.85 (0.58,
1.26)
0.419 0.84 (0.61,
1.15)
0.276
Fluid (per 1000ml) 1.00 (0.52,
1.95)
.994 1.02 (0.57,
1.81)
.961 1.25 (0.74,
2.10)
0.399 1.02 (0.53,
1.96)
0.953
Norepinephrine (per 0.1μg/kg/min) 3.06 (1.42,
6.60)
.004 1.36 (0.87,
2.13)
.176 1.34 (0.89,
2.04)
0.166 2.37 (1.07,
5.25)
0.034
(IGFBP7) * (TIMP-2) level (per 0.1 unit log) 1.33 (1.17,
1.52)
<.001 1.17 (1.01,
1.36)
.043 1.10 (0.96,
1.15)
0.167 1.20 (1.07,
1.36)
0.003
AUC (95%-CI) 0.892 (0.829, 0.956) 0.858 (0.729, 0.986) 0.810 (0.693, 0.927) 0.892 (0.812, 0.973)
AUC (95%-CI) without (IGFBP7) * (TIMP-2)
level
0.811 (0.725, 0.897) 0.847 (0.694, 1.000) 0.754 (0.571, 0.936) 0.868 (0.775, 0.962)
p-value* <0.001 0.035 0.167 0.002
*Likelihood-ratio test (comparing the ﬁt of both models)
AKI, acute kidney injury; RRT, renal replacement therapy; IGFBP7, insulin-like growth factor-binding protein 7; TIMP-2, tissue inhibitor of
metalloproteinase; MAP, mean arterial pressure, AUC, area under the curve; CI, coincidence interval; OR, odds ratio.
doi:10.1371/journal.pone.0120863.t004
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bedside postoperative factors). Our results showed that the [TIMP-2]×[IGFBP7] test was the
strongest predictor of AKI. Use of these biomarkers alone or in combination with established
perioperative risk factors markedly improved early risk assessment.
The addition of the [TIMP-2]×[IGFBP7] test to clinical models for assessing the risk of
28-days mortality improved prediction in both models (AUC from 0.76 to 0.81 and from 0.80
to 0.83 respectively). However, this association was statistically not significant. The median
value of the [TIMP-2]×[IGFBP7] test for patients dying within 28 days after surgery was lower
than the median value for patients developing AKI stage 2–3 and for patients receiving RRT.
This finding highlights the fact that the [TIMP-2]×[IGFBP7] test is primarily an AKI risk as-
sessment tool. However, these findings support recent data suggesting that early cell cycle risk
arrest in the kidneys may be associated with adverse outcome [25].
Interestingly, in the subgroup of patients after major hepatic surgery, relatively high median
values of biomarkers of cellular injury contrasted with only one consecutive case of AKI within
48 hours after surgery. Application of a low CVP strategy is an effective and recommended
method to reduce blood loss during liver surgery [26]. However, restrictive volume anesthesia
is associated with an increased risk of acute renal failure in a postoperative setting [27]. There-
fore, patients after liver resection are given higher amount of fluids in the early postoperative
period to prevent prolonged perioperative hypoperfusion. In our study, the hepatic surgery
subgroup had an unproportionally high mean positive fluid balance within first 24 hours post-
operatively if compared to patients after cancer surgery with very similar baseline characteris-
tics (1419 vs. 939 ml/24h). This fact may indirectly indicate that the early correction of
hypovolemia may reverse early cell cycle arrest and prevent development of AKI.
Our study has several limitations. We conducted the study in one single surgical ICU. How-
ever, we believe that we examined a representative cohort of non-cardiac surgical patients. Our
results showed higher rates of AKI (>42%) as well as early use of RRT (>10%). The high inci-
dence of AKI − that may influence the predictive performance of biomarkers − was due to the
study design that only included patients with a high risk of AKI. The previous two multicenter
studies, however, have shown the ability of the [TIMP-2]×[IGFBP7] test to provide risk stratifi-
cation for moderate and severe AKI in over 1100 critically ill patients with a prevalence of AKI,
which was similar to that described in other literature reports. Moreover, another recent study
has shown a very similar incidence of postoperative AKI of 39% in the cohort of 50 314 patients
after major surgery [28]. Finally, we did not evaluate the long-term outcome (>28 days) in pa-
tients with cellular injury detected with [TIMP-2]×[IGFBP7] test. These issues need to be in-
vestigated in future studies.
In summary, we showed that the [TIMP-2]×[IGFBP7] test significantly improves the early
prediction of any type of AKI in high-risk surgical patients. Due to its rapid responsiveness, the
test extends the therapeutic window for renal protection measurements or future therapeutic
interventions to prevent the development of AKI. Together with the known risk factors and
bedside clinical parameters, this test helps clinicians more accurately identify patients who
should consequently receive renal protective measures and escalation of care. Particularly post-
operative hemodynamic optimization seems to decrease the risk of renal impairment in surgi-
cal patients [29]. This process could be started very early after surgery in patients with cellular
stress diagnosed by means of urinary biomarkers. Future studies are required to determine
whether early and more accurate risk stratification is consistently associated with better out-
come for surgical patients with AKI.
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